Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review

Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review

Background: Lung adenocarcinoma with the classical EGFR 19 deletion and exon 21 L858R point mutations has exhibited good responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, the sensitivity of uncommon EGFR exon 20 insertion mutation to third-gener...

Full description

Bibliographic Details
Main Authors: Xiao Zhang, Huan Han, Jiuzhou Zhao, Xiao Liu, Jianbo Zhang, Rui Sun, Shaomei Li, Baoxing Liu, Hui Zhu, Shuyue Jiao, Xiang Li, Hong Tang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
NSCLC
EGFR exon 20 insertion mutation
N771_P772insH
furmonertinib
second-line
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.964606/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.964606/full

Similar Items